Decreased serum apolipoprotein A1 level predicts poor prognosis of patients with de novo myelodysplastic syndromes

• Published in: BMC cancer 2022-01, Vol.22 (1), p.127-127, Article 127
• Main Authors: Shi, Cong, Gong, Shengping, Wu, An, Yang, Shujun, Zou, Duobing, Zhang, Yi, Wu, Ningning, Ma, Chao, Shi, Songqiu, Chen, Ying, Wu, Ying, Zheng, Xiaojiao, Huang, Zhenya, Ding, Jianghua, Ouyang, Guifang, Mu, Qitian
• Format: Article
• Language: English
• Subjects: Aged; Apolipoprotein A-I - blood; Apolipoproteins; Bone marrow; Cancer therapies; Diagnosis; Disease; Female; Genes; Health aspects; Hematopoietic stem cells; Hemoglobin; High density lipoprotein; Hormone replacement therapy; Humans; IPSS-R; Karyotypes; Laboratories; Leukemia; Lipids; Male; Measurement; Medical prognosis; Metabolism; Metabolites; Metastasis; Middle Aged; Morphology; Mutation; Myelodysplastic syndrome; Myelodysplastic syndromes; Myelodysplastic Syndromes - blood; Myelodysplastic Syndromes - mortality; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Serum ApoA1; Stem cells; TP53; Tumorigenesis; Tumors
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-022-09248-2

Myelodysplastic syndromes (MDS) is a group of heterogeneous myeloid clonal diseases originating from hematopoietic stem cells. It has been demonstrated that apolipoproteins A1(ApoA1) are associated with disease risk in many cancer types. However, there still lacks evidence regarding the link between ApoA1 and MDS. This study was designed to investigate the prognostic value of pretreatment ApoA1 levels in MDS patients. We retrospectively analyzed a cohort of 228 MDS patients to explore the prognostic value of the serum ApoA1 levels at diagnosis. Patients were divided into the high ApoA1 group and the low ApoA1 group. The prognostic significance was determined by univariate and multivariate Cox hazard models. MDS patients with low ApoA1 levels had significantly shorter overall survival (OS, P